Loading clinical trials...

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease

NCT00163085•Pfizer

View on ClinicalTrials.gov

Summary

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Eligibility

Age

30 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state.

Exclusion Criteria

•Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Locations (1)

Pfizer Investigational Site

Portland, Oregon, United States

Key Dates

Start Date

May 1, 2005

Completion Date

January 1, 2006

Last Updated

September 22, 2006

Enrollment

Estimated participants

Conditions

Parkinson's Disease

Interventions

NR2B NMDA Antagonist CP-101,606 (traxoprodil)

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 22, 2006Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Deep Brain Stimulation Therapy in Movement Disorders

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations